Gene basic information

symbol GAS5
name growth arrest specific 5 (non-protein coding)
location 1q25.1
alias_symbol SNHG2|NCRNA00030
alias_name small nucleolar RNA host gene (non-protein coding) 2|non-protein coding RNA 30
Tissuebladder,bone marrow,breast,cervix,colorectum,endometrium,kidney,liver,lung,nervous system,others,ovary,pancreas,pleura,prostate,stomach,
Cancerbladder cancer,breast cancer,cervical cancer,colorectal cancer,endometrial cancer,gastric cancer,glioma,hepatic cancer,lung adenocarcinoma,malignant pleural mesothelioma,mantle cell lymphoma cell,melanoma,non-small-cell lung cancer,ovarian cancer,pancreatic cancer,prostate cancer,renal cancer,


LncRNA GAS5 is a tumor suppressor gene. GAS5 level is significantly down-regulated in glioma (1), melanoma (2), mantle cell lymphoma cell (3), lung cancer (4), malignant pleural mesothelioma (5), breast cancer (6), gastric cancer (7,8,9), liver cancer (10,11,12), pancreatic cancer (13), colorectal cancer(14), cervical cancer (15), endometrial cancer (16), bladder cancer (17,18), prostate cancer (19) and renal cell carcinoma(20). Low GAS5 level is associated with tumor size, lymph node metastasis, TNM stage, deeper depth of invasion and poor prognosis (15, 7, 8, 9, 10, 11, 12, 14). Functionally, GAS5 can inhibit proliferation, migration, invasion and apoptosis of various cancer cells (17, 18, 15, 7, 8, 9, 1, 12, 2, 13, 20, 14). It can directly bind with miR-103 (16), miR-21 (11), miR-122 (1) to act as a ceRNA. GAS5 can also negatively regulate CDK6, CCL1 (17, 9, 18), Notch-1 (6), E2F1, cyclinD1 (7), bmf, Plexin C1 (1), vimentin (12) and MMP2 (2) and positively regulate PTEN (11), p21 (8, 9) and PDCD4 (11). We can confirm that GAS5 plays these regulatory functions by directly binding to miRNAs, or by regulating proliferation-, invasion- and metastasis-related factors.
Besides,GAS5 affects chemotherapy response in multiple cancers (21, 22, 23, 24, 5, 19). Moreover, polymorphism in the promoter region of GAS5 may contribute to carcinogenesis (25).

Cancer related information

download as excel csv txt

LncRNA tissue cancer type expression level oncogene/suppress gene pathway binding gene/factor associated gene/factor proliferation apoptosis migration EMT invasion metastasis prognosis tag PMID
0 GAS5 breast breast cancer down TS caspase-8+,caspase-9+ + 18836484
1 GAS5 kidney renal cancer down TS - - - 23621190
2 GAS5 prostate prostate cancer down TS + chemotherapy resistance 23676682
3 GAS5 pancreas pancreatic cancer down TS CDK6- - 24026436
4 GAS5 bladder bladder cancer down TS CDK6- - 24069260
5 GAS5 lung non-small-cell lung cancer down TS p53+,p21+,E2F1-,cyclinD1- - + epigenetic modification 24357161
6 GAS5 bone marrow mantle cell lymphoma cell down TS mTOR- - + 24703244
7 GAS5 breast breast cancer down TS + chemotherapy resistance 24789445
8 GAS5 stomach gastric cancer down TS E2F1-,cyclinD1- - + 24884417
9 GAS5 pleura malignant pleural mesothelioma down / - chemotherapy resistance 24885398
10 GAS5 colorectum colorectal cancer / / miR-34a+,+p53 chemotherapy resistance 24926850
11 GAS5 colorectum colorectal cancer / / SNP 27863421
12 GAS5 liver hepatic cancer down TS + 25120813
13 GAS5 colorectum colorectal cancer down TS - - 25326054
14 GAS5 cervix cervical cancer down TS - - - + 25400758
15 GAS5 prostate prostate cancer down TS -mTOR inhibitors hormonal resistance 25650269
16 GAS5 lung lung adenocarcinoma down / IGF-1R- drug resistance 25925741
17 GAS5 stomach gastric cancer down TS YBX1 p21+ 25959498
18 GAS5 stomach gastric cancer down TS miR-23a+ 27827524
19 GAS5 liver hepatic cancer / / SNP 26163879
20 GAS5 stomach gastric cancer down TS p21+,CDK6- 26278580
21 GAS5 nervous system glioma down TS miR-222- bmf-,Plexin C1- + - - 26370254
22 GAS5 liver hepatic cancer down TS miR-21- PDCD4+,PTEN+ - - + 26404135
23 GAS5 ovary ovarian cancer down TS Bax+,Bak+,caspase-3+,caspase-9+ - + - - 26503132
24 GAS5 endometrium endometrial cancer down TS miR-103- PTEN+ - - 26511107
25 GAS5 bladder bladder cancer down TS CCL1- - 26548923
26 GAS5 breast breast cancer / / Notch-1- 26550436
27 GAS5 liver hepatic cancer down TS vimentin- - + - + 26707238
28 GAS5 others melanoma down TS MMP2- - - 26846479
29 GAS5 breast breast cancer / / 26862727
30 GAS5 breast breast cancer down TS mTOR miR-21 PTEN+ - - + chemotherapy resistance 27034004
31 GAS5 lung non-small-cell lung cancer down / chemotherapy resistance 27338051

Expression profile

adipose adrenal brain breast colon heart kidney leukocyte liver lung lymph node ovary prostate skeletal muscle testis thyroid tissue 0 20 40 60 80 100 120 140 fpkm 33.0 55.0 15.0 35.0 48.0 4.0 18.0 34.0 7.0 55.0 54.0 137.0 61.0 10.0 36.0 33.0 GAS5

Expression profile in human body map


Expression profile in TCGA

Genomic feature visualization


External link


[1]. Zhao X, Wang P, Liu J, Zheng J, Liu Y, et al. (2015). Gas5 Exerts Tumor-suppressive Functions in Human Glioma Cells by Targeting miR-222. Mol Ther 23(12): 1899-911. link pubmed
[2]. Chen L, Yang H, Xiao Y, Tang X, Li Y, et al. (2016). Lentiviral-mediated overexpression of long non-coding RNA GAS5 reduces invasion by mediating MMP2 expression and activity in human melanoma cells. Int J Oncol 48(4): 1509-18. link pubmed
[3]. Mourtada-Maarabouni M, Williams GT (2014). Role of GAS5 noncoding RNA in mediating the effects of rapamycin and its analogues on mantle cell lymphoma cells. Clin Lymphoma Myeloma Leuk 14(6): 468-73. link pubmed
[4]. Shi X, Sun M, Liu H, Yao Y, Kong R, et al. (2015). A critical role for the long non-coding RNA GAS5 in proliferation and apoptosis in non-small-cell lung cancer. Mol Carcinog 54 Suppl 1: E1-E12. link pubmed
[5]. Renganathan A, Kresoja-Rakic J, Echeverry N, Ziltener G, Vrugt B, et al. (2014). GAS5 long non-coding RNA in malignant pleural mesothelioma. Mol Cancer 13: 119. link pubmed
[6]. Pei J, Wang B (2015). Notch-1 promotes breast cancer cells proliferation by regulating LncRNA GAS5. Int J Clin Exp Med 8(8): 14464-71. link pubmed
[7]. Sun M, Jin FY, Xia R, Kong R, Li JH, et al. (2014). Decreased expression of long noncoding RNA GAS5 indicates a poor prognosis and promotes cell proliferation in gastric cancer. BMC Cancer 14: 319. link pubmed
[8]. Liu Y, Zhao J, Zhang W, Gan J, Hu C, et al. (2015). lncRNA GAS5 enhances G1 cell cycle arrest via binding to YBX1 to regulate p21 expression in stomach cancer. Sci Rep 5: 10159. link pubmed
[9]. Guo X, Deng K, Wang H, Xia J, Shan T, et al. (2015). GAS5 Inhibits Gastric Cancer Cell Proliferation Partly by Modulating CDK6. Oncol Res Treat 38(7-8): 362-6. link pubmed
[10]. Tu ZQ, Li RJ, Mei JZ, Li XH (2014). Down-regulation of long non-coding RNA GAS5 is associated with the prognosis of hepatocellular carcinoma. Int J Clin Exp Pathol 7(7): 4303-9. link pubmed
[11]. Hu L, Ye H, Huang G, Luo F, Liu Y, et al. (2016). Long noncoding RNA GAS5 suppresses the migration and invasion of hepatocellular carcinoma cells via miR-21. Tumour Biol 37(2): 2691-702. link pubmed
[12]. Chang L, Li C, Lan T, Wu L, Yuan Y, et al. (2016). Decreased expression of long non-coding RNA GAS5 indicates a poor prognosis and promotes cell proliferation and invasion in hepatocellular carcinoma by regulating vimentin. Mol Med Rep 13(2): 1541-50. link pubmed
[13]. Lu X, Fang Y, Wang Z, Xie J, Zhan Q, et al. (2013). Downregulation of gas5 increases pancreatic cancer cell proliferation by regulating CDK6. Cell Tissue Res 354(3): 891-6. link pubmed
[14]. Yin D, He X, Zhang E, Kong R, De W, et al. (2014). Long noncoding RNA GAS5 affects cell proliferation and predicts a poor prognosis in patients with colorectal cancer. Med Oncol 31(11): 253. link pubmed
[15]. Cao S, Liu W, Li F, Zhao W, Qin C (2014). Decreased expression of lncRNA GAS5 predicts a poor prognosis in cervical cancer. Int J Clin Exp Pathol 7(10): 6776-83. link pubmed
[16]. Guo C, Song WQ, Sun P, Jin L, Dai HY (2015). LncRNA-GAS5 induces PTEN expression through inhibiting miR-103 in endometrial cancer cells. J Biomed Sci 22: 100. link pubmed
[17]. Liu Z, Wang W, Jiang J, Bao E, Xu D, et al. (2013). Downregulation of GAS5 promotes bladder cancer cell proliferation, partly by regulating CDK6. PLoS One 8(9): e73991. link pubmed
[18]. Cao Q, Wang N, Qi J, Gu Z, Shen H (2016). Long non‑coding RNA‑GAS5 acts as a tumor suppressor in bladder transitional cell carcinoma via regulation of chemokine (C‑C motif) ligand 1 expression. Mol Med Rep 13(1): 27-34. link pubmed
[19]. Pickard MR, Mourtada-Maarabouni M, Williams GT (2013). Long non-coding RNA GAS5 regulates apoptosis in prostate cancer cell lines. Biochim Biophys Acta 1832(10): 1613-23. link pubmed
[20]. Qiao HP, Gao WS, Huo JX, Yang ZS (2013). Long non-coding RNA GAS5 functions as a tumor suppressor in renal cell carcinoma. Asian Pac J Cancer Prev 14(2): 1077-82. link pubmed
[21]. Li W, Zhai L, Wang H, Liu C, Zhang J, et al. (2016). Downregulation of LncRNA GAS5 causes trastuzumab resistance in breast cancer. Oncotarget 7(19): 27778-86. link pubmed
[22]. Pickard MR, Williams GT (2014). Regulation of apoptosis by long non-coding RNA GAS5 in breast cancer cells: implications for chemotherapy. Breast Cancer Res Treat 145(2): 359-70. link pubmed
[23]. Krell J, Frampton AE, Mirnezami R, Harding V, De Giorgio A, et al. (2014). Growth arrest-specific transcript 5 associated snoRNA levels are related to p53 expression and DNA damage in colorectal cancer. PLoS One 9(6): e98561. link pubmed
[24]. Dong S, Qu X, Li W, Zhong X, Li P, et al. (2015). The long non-coding RNA, GAS5, enhances gefitinib-induced cell death in innate EGFR tyrosine kinase inhibitor-resistant lung adenocarcinoma cells with wide-type EGFR via downregulation of the IGF-1R expression. J Hematol Oncol 8: 43. link pubmed
[25]. Tao R, Hu S, Wang S, Zhou X, Zhang Q, et al. (2015). Association between indel polymorphism in the promoter region of lncRNA GAS5 and the risk of hepatocellular carcinoma. Carcinogenesis 36(10): 1136-43. link pubmed

© Bioinformatics Group of XTBG